Inhibition of TYK2 in Skin Autoimmune Disorders: Achieving Remission of Discoid Lupus and Psoriasis with Deucravacitinib and Complementary Confocal Microscopy Evidence - Takeaways - MDSpire

Inhibition of TYK2 in Skin Autoimmune Disorders: Achieving Remission of Discoid Lupus and Psoriasis with Deucravacitinib and Complementary Confocal Microscopy Evidence

  • By

  • Francesco D’Oria

  • Francesco Piscazzi

  • Paola Facheris

  • Giulio Foggi

  • Marco Ardigò

  • Antonio Costanzo

  • Mario Valenti

  • April 9, 2026

  • 0 min

Share

  • 1

    Deucravacitinib achieved complete remission in a patient with treatment-refractory discoid lupus erythematosus and plaque psoriasis.

  • 2

    Inhibition of TYK2 targets type I interferon pathways, crucial in the pathogenesis of cutaneous lupus erythematosus.

  • 3

    Reflectance confocal microscopy confirmed the resolution of active inflammatory changes in the patient's skin.

  • 4

    This case supports deucravacitinib as a promising targeted therapy for refractory cutaneous lupus erythematosus.

  • 5

    Current treatments for cutaneous lupus erythematosus are limited, highlighting the need for new therapeutic options.

Original Source(s)

Inhibition of TYK2 in Skin Autoimmune Disorders: Achieving Remission of Discoid Lupus and Psoriasis with Deucravacitinib and Complementary Confocal Microscopy Evidence

  • by Francesco D’Oria, Francesco Piscazzi, Paola Facheris, Giulio Foggi, Marco Ardigò, Antonio Costanzo, Mario Valenti

  • April 9, 2026

Related Content

FDA Approves New Oral Option for Plaque Psoriasis

Phase 3 data showed high skin clearance rates and adverse event rates similar to placebo through week 16 with once-daily icotrokinra.

AI Scribes Lag Clinicians on Note Quality

A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness

AI Falls Short on Differential Dx

New PrIME-LLM benchmark shows strong diagnostic accuracy but persistent gaps in clinical reasoning across 21 large language models